HomeNewsNeuroscience

  • FDA re-examining safety of Nuplazid post reports of spike in adverse event

    • April 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Phase 2 Clinical Trial of GRF6019 in Alzheimer’s Disease initiated by Alkahest

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Galcanezumab reduces Migraine days for patients failing on other therapies, highlights new subgroup analysis

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2 results of Ublituximab (TG-1101) in MS patients announced by TG Therapeutics at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2b trial results of MN-166 (ibudilast) in Progressive MS presented at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New Epilepsy research to find Biomarkers for Treatment of Focal Seizures in patients

    • April 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New guidelines for starting MS treatment early and switching issued at AAN 2018

    • April 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • AOBiome initiates Ph 2 trial for episodic migraine

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Strong clinical data with single dose rimegepant in acute treatment of migraine announced by Biohaven

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Switches from Injectables to Fingolimod associated with lower relapse risks, underlines new study

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more